Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie maintains recent growth momentum in Q3 2013

AbbVie maintains recent growth momentum in Q3 2013

31st October 2013

AbbVie has expressed satisfaction with the success of its business strategy during the third quarter of 2013, a period marked by year-on-year growth for the business.

The company's worldwide sales total for the quarter came to $4.66 billion (2.91 billion pounds), up by 3.3 percent on Q3 2012, with growth driven by the ongoing success of its multipurpose therapy Humira, as well as Synthroid, Creon, Zemplar and Duodopa.

During the quarter, AbbVie made significant progress toward the completion of its phase III interferon-free hepatitis C programme and presented positive data from various clinical trials, while agreeing a new global alliance with Galapagos.

The firm has now raised its full-year outlook for 2013 on the strength of its recent performance.

Richard Gonzalez, chairman and chief executive officer at AbbVie, said: "Our mid to late-stage pipeline contains a number of potentially significant opportunities and we look forward to a series of milestones across our pipeline in the coming months."

AbbVie has showed a consistently strong financial performance since it was established as an independent company by former parent Abbott at the start of the year.ADNFCR-8000103-ID-801655508-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.